Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate. Last month, the agency knocked back an approval application for ...

Disc Medicine develops novel therapeutics targeting hematologic diseases, with a pipeline focused on red blood cell biology, heme biosynthesis, and iron homeostasis. The company operates a ...

Feb 13 (Reuters) - Disc Medicine (IRON.O), opens new tab said on Friday the U.S. Food and Drug Administration declined to approve its drug to treat a rare genetic disorder. The drug, bitopertin, was ...

The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that had been granted expedited review through a newly launched priority voucher program. While the agency agreed ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. Adam Feuerstein is a senior ...

This article was co-authored with Emma Myer, a student at Washington and Lee University who studies Cognitive/Behavioral Science and Strategic Communication. In today’s digital age, social media has ...

While the creation of this new entity marks a big step toward avoiding a U.S. ban, as well as easing trade and tech-related tensions between Washington and Beijing, there is still uncertainty ...

Four small satellites rode a Rocket Lab Electron launch vehicle into orbit from Virginia early Thursday, beginning a government-funded technology demonstration mission to test the performance of a new ...

A lab worker wearing face mask, safety spectacles and hair net looks intently at a pipette Disc Medicine has repurposed a drug candidate originally developed for schizophrenia and pointed it squarely ...

As the world races to build artificial superintelligence, one maverick bioengineer is testing how much unprogrammed intelligence may already be lurking in our simplest algorithms to determine whether ...